Zealand Pharma A/S
CSE:ZEAL
Gross Margin
Zealand Pharma A/S
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| DK |
|
Zealand Pharma A/S
CSE:ZEAL
|
32.7B DKK |
93%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
0%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
330.7B USD |
71%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
155.7B USD |
64%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
136B USD |
78%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.7B USD |
86%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
76%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
118.8B AUD |
52%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
52.8B USD |
87%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
75%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
39.9B USD |
86%
|
Zealand Pharma A/S
Glance View
Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Zealand Pharma A/S's most recent financial statements, the company has Gross Margin of 93.4%.
You don't have any saved screeners yet